Современный опыт фармакотерапии синдрома раздраженного кишечника у детей

В данном обзоре рассматриваются современные подходы к диагностике и лечению синдрома раздраженного кишечника (СРК) у детей — одного из наиболее распространенных функциональных расстройств ЖКТ. СРК характеризуется хроническими абдоминальными болями, нарушениями моторики кишечника и изменениями стула, что существенно снижает качество жизни пациентов. В статье подробно анализируются патогенетические механизмы СРК, включая роль оси «кишечник – мозг», микробиоты кишечника и нейроэндокринных факторов. Особое внимание уделено фармакотерапии СРК у детей, включая использование антидепрессантов, пробиотиков и растительных компонентов, а также роли корректоров моторной деятельности пищеварительного тракта в купировании симптомов. Рассмотрены современные рекомендации по применению различных классов антидепрессантов с учетом их фармакокинетических и фармакодинамических особенностей. Также анализируются перспективы использования пробиотиков и растительных препаратов в комплексной терапии СРК. Полученные данные подтверждают необходимость персонализированного подхода к лечению СРК с учетом генетических и физиологических особенностей пациентов.

1. Alyasi AS, Altawili MA, Alabbadi AF, et al. Pharmacological Management for Pediatric Irritable Bowel Syndrome: A Review. Cureus. 2023;15(11):e49197. https://doi.org/10.7759/cureus.49197

2. Halland M, Saito YA. Irritable bowel syndrome: new and emerging treatments. BMJ. 2015;350:h1622. https://doi.org/10.1136/bmj.h1622

3. Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med. 2017;6(11):99. https://doi.org/10.3390/jcm6110099

4. Hyams JS, Di Lorenzo C, Saps M, et al. Functional Disorders: Children and Adolescents. Gastroenterology. 2016:S00165085(16)00181-5. https://doi.org/10.1053/j.gastro.2016.02.015

5. Soares RL. Irritable bowel syndrome: a clinical review. World J Gastroenterol. 2014;20(34):12144–12160. https://doi.org/10.3748/wjg.v20.i34.12144

6. Yu SJ, Lee HS, Gung HJ, et al. IBS Research Study Group of the Korean Society of Neurogastroenterology and Motility. Efficacy of a Restrictive Diet in Irritable Bowel Syndrome: A Systematic Review and Network Meta-analysis. Korean J Gastroenterol. 2022;80(1):6– 16. https://doi.org/10.4166/kjg.2022.014

7. Ng QX, Soh AYS, Loke W, et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018;11:345–349. https://doi.org/10.2147/JIR.S174982

8. Rowland I, Gibson G, Heinken A, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018;57(1):1–24. https://doi.org/10.1007/s00394-0171445-8

9. Gill PA, Inniss S, Kumagai T, et al. The Role of Diet and Gut Microbiota in Regulating Gastrointestinal and Inflammatory Disease. Front Immunol. 2022;13:866059. https://doi.org/10.3389/fimmu.2022.866059

10. Korterink JJ, Diederen K, Benninga MA, Tabbers MM. Epidemiology of pediatric functional abdominal pain disorders: a meta-analysis. PLoS One. 2015;10(5):e0126982. https://doi.org/10.1371/journal.pone.0126982

11. Rughwani T. Current Awareness and Tools Available for StressInduced IBS in Children. 2024. In: Digital Commons @ Garrisburg University: Website. Available online: https://digitalcommons.harrisburgu.edu/dandt/13. Accessed on August 31, 2024.

12. Chogle A, Mintjens S, Saps M. Pediatric IBS: an overview on pathophysiology, diagnosis and treatment. Pediatr Ann. 2014;43(4):e76–e82. https://doi.org/10.3928/0090448120140325-08

13. Algera J, Lövdahl J, Sjölund J, et al. Managing pain in irritable bowel syndrome: current perspectives and best practice. Expert Rev Gastroenterol Hepatol. 2023;17(9):871–881. https://doi.org/10.1080/17474124.2023.2242775

14. Jing F, Zhang J. Metabolic kinetics of 5-hydroxytryptamine and the research targets of functional gastrointestinal disorders. Dig Dis Sci. 2014;59(11):2642–2648. https://doi.org/10.1007/s10620-014-3244-x

15. Chen M, Ruan G, Chen L, et al. Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome. Front Endocrinol (Lausanne). 2022;13:817100. https://doi.org/10.3389/fendo.2022.817100

16. Fu R, Chen M, Chen Y, et al. Expression and clinical significance of 5-HT and 5-HT3R in the intestinal mucosa of patient with diarrhea-type irritable bowel syndrome. Exp Ther Med. 2019;17(4):3077–3082. https://doi.org/10.3892/etm.2019.7297

17. Stasi C, Bellini M, Gambaccini D, et al. Neuroendocrine Dysregulation in Irritable Bowel Syndrome Patients: A Pilot Study. J Neurogastroenterol Motil. 2017;23(3):428–434. https://doi.org/10.5056/jnm16155

18. Kridler J, Kamat D. Irritable Bowel Syndrome: A Review for General Pediatricians. Pediatr Ann. 2016;45(1):e30–e33. https://doi.org/10.3928/00904481-20151208-01

19. Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145(6):1262–1270.e1. https://doi.org/10.1053/j.gastro.2013.08.048

20. Palsson OS, Whitehead WE, van Tilburg MA, et al. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology. 2016:S0016-5085(16)00180-3. https://doi.org/10.1053/j.gastro.2016.02.014

21. Singh SV, Ganguly R, Jaiswal K, et al. Molecular signalling during cross talk between gut brain axis regulation and progression of irritable bowel syndrome: A comprehensive review. World J Clin Cases. 2023;11(19):4458–4476. https://doi.org/10.12998/wjcc.v11.i19.4458

22. Appleton J. The Gut-Brain Axis: Influence of Microbiota on Mood and Mental Health. Integr Med (Encinitas). 2018;17(4):28–32.

23. Mayer EA, Ryu HJ, Bhatt RR. The neurobiology of irritable bowel syndrome. Mol Psychiatry. 2023;28(4):1451–1465. https://doi.org/10.1038/s41380-023-01972-w

24. Cerdó T, García-Santos JA, Rodríguez-Pöhnlein A, et al. Impact of Total Parenteral Nutrition on Gut Microbiota in Pediatric Population Suffering Intestinal Disorders. Nutrients. 2022;14(21):4691. https://doi.org/10.3390/nu14214691

25. Craven LJ, Silverman M, Burton JP. Transfer of altered behaviour and irritable bowel syndrome with diarrhea (IBS-D) through fecal microbiota transplant in mouse model indicates need for stricter donor screening criteria. Ann Transl Med. 2017;5(24):490. https://doi.org/10.21037/atm.2017.10.03

26. De Palma G, Lynch MD, Lu J, et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med. 2017;9(379):eaaf6397. https://doi.org/10.1126/scitranslmed.aaf6397

27. Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. World J Gastroenterol. 2018;24(21):2211–2235. https://doi.org/10.3748/wjg.v24.i21.2211

28. Donnet AS, Hasan SS, Whorwell PJ. Hypnotherapy for irritable bowel syndrome: patient expectations and perceptions. Therap Adv Gastroenterol. 2022;15:17562848221074208. https://doi.org/10.1177/17562848221074208

29. Rexwinkel R, de Bruijn CMA, Gordon M, et al. Pharmacologic Treatment in Functional Abdominal Pain Disorders in Children: A Systematic Review. Pediatrics. 2021;147(6):e2020042101. https://doi.org/10.1542/peds.2020-042101

30. Dwyer JB, Bloch MH. Antidepressants for Pediatric Patients. Curr Psychiatr. 2019;18(9):26–42F.

31. Bonilla S, Nurko S. Focus on the use of antidepressants to treat pediatric functional abdominal pain: current perspectives. Clin Exp Gastroenterol. 2018;11:365–372. https://doi.org/10.2147/CEG.S146646

32. Deodhar M, Rihani SBA, Darakjian L, et al. Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition. Pharmaceutics. 2021;13(2):148. https://doi.org/10.3390/pharmaceutics13020148

33. Huang X, Li C, Li C, et al. CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population. Front Pharmacol. 2021;12:730461. https://doi.org/10.3389/fphar.2021.730461

34. Maciaszek J, Pawłowski T, Hadryś T, et al. The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression. Int J Mol Sci. 2023;24(17):13459. https://doi.org/10.3390/ijms241713459

35. Ford AC, Wright-Hughes A, Alderson SL, et al. ATLANTIS trialists. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773–1785. https://doi.org/10.1016/S0140-6736(23)01523-4

36. Nassan M, Nicholson WT, Elliott MA, et al. Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. Mayo Clin Proc. 2016;91(7):897–907. https://doi.org/10.1016/j.mayocp.2016.02.023

37. Dean L. Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype. In: Medical Genetics Summaries. Pratt VM, Scott SA, Pirmohamed M, et al., eds. Bethesda (MD): National Center for Biotechnology Information (US); 2017.

38. Radosavljevic M, Svob Strac D, Jancic J, Samardzic J. The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy. Genes (Basel). 2023;14(5):1095. https://doi.org/10.3390/genes14051095

39. Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023;24(6):350–362. https://doi.org/10.1038/s41576-022-00572-8

40. Thümmler S, Dor E, David R, et al. Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6. Front Psychiatry. 2018;9:2. https://doi.org/10.3389/fpsyt.2018.00002

41. Austin-Zimmerman I, Wronska M, Wang B, et al. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics. Genes (Basel). 2021;12(11):1758. https://doi.org/10.3390/genes12111758

42. Lam D, Ancelin ML, Ritchie K, et al. Genotype-dependent associations between serotonin transporter gene (SLC6A4) DNA methylation and late-life depression. BMC Psychiatry. 2018;18(1):282. https://doi.org/10.1186/s12888-018-1850-4

43. Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry. 2010;68(6):536–543. https://doi.org/10.1016/j.biopsych.2010.04.034

44. Jukic M, Milosavljević F, Molden E, Ingelman-Sundberg M. Pharmacogenomics in treatment of depression and psychosis: an update. Trends Pharmacol Sci. 2022;43(12):1055–1069. https://doi.org/10.1016/j.tips.2022.09.011

45. Aka I, Bernal CJ, Carroll R, et al. Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. J Pers Med. 2017;7(4):14. https://doi.org/10.3390/jpm7040014

46. Lu PL, Velasco-Benítez CA, Saps M. Sex, Age, and Prevalence of Pediatric Irritable Bowel Syndrome and Constipation in Colombia: A Population-based Study. J Pediatr Gastroenterol Nutr. 2017;64(6):e137–e141. https://doi.org/10.1097/MPG.0000000000001391

47. Karunanayake A, Devanarayana NM, Rajindrajith S. Early life events in functional abdominal pain disorders in children. PLoS One. 2022;17(11):e0275419. https://doi.org/10.1371/journal.pone.0275419

48. Koppen IJ, Nurko S, Saps M, et al. The pediatric Rome IV criteria: what’s new? Expert Rev Gastroenterol Hepatol. 2017;11(3):193–201. https://doi.org/10.1080/17474124.2017.1282820

49. Trinkley KE, Nahata MC. Medication management of irritable bowel syndrome. Digestion. 2014;89(4):253–267. https://doi.org/10.1159/000362405

50. Roohafza H, Pourmoghaddas Z, Saneian H, Gholamrezaei A. Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial. Neurogastroenterol Motil. 2014;26(11):1642–1650. https://doi.org/10.1111/nmo.12444

51. Seetharaman J, Poddar U, Yachha SK, et al. Efficacy of amitriptyline in pediatric functional abdominal pain disorders: A randomized placebo-controlled trial. J Gastroenterol Hepatol. 2022;37(4):685–691. https://doi.org/10.1111/jgh.15765

52. Saps M, Youssef N, Miranda A, et al. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology. 2009;137(4):1261–1269. https://doi.org/10.1053/j.gastro.2009.06.060

53. Crawford J, Tran P, Shaw JS, Shaw RJ. Current Pharmacological Treatments for Childhood-Onset Somatic Symptom and Related Disorders (SSRD) and Functional Gastrointestinal Disorders (FGID). Current Treatment Options in Psychiatry. 2020;7:120–143. https://doi.org/10.1007/s40501-020-00209-9

54. Guandalini S, Magazzù G, Chiaro A, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51(1):24–30. https://doi.org/10.1097/MPG.0b013e3181ca4d95

55. Sudha MR, Jayanthi N, Aasin M, et al. Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. Benef Microbes. 2018;9(4):563–572. https://doi.org/10.3920/BM2017.0129

56. Francavilla R, Miniello V, Magistà AM, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics. 2010;126(6):e1445–e1452. https://doi.org/10.1542/peds.2010-0467

57. Menon J, Thapa BR, Kumari R, et al. Efficacy of Oral Psyllium in Pediatric Irritable Bowel Syndrome: A Double-Blind Randomized Control Trial. J Pediatr Gastroenterol Nutr. 2023;76(1):14–19. https://doi.org/10.1097/MPG.0000000000003622

58. Shulman RJ, Hollister EB, Cain K, et al. Psyllium Fiber Reduces Abdominal Pain in Children With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. Clin Gastroenterol Hepatol. 2017;15(5):712–719.e4. https://doi.org/10.1016/j.cgh.2016.03.045

59. Ogawa N, Nakajima S, Tamada K, et al. Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages. Arch Biochem Biophys. 2021;711:109029. https://doi.org/10.1016/j.abb.2021.109029

60. Karabulut GS, Beşer OF, Erginöz E, et al. The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment. J Neurogastroenterol Motil. 2013;19(1):90–93. https://doi.org/10.5056/jnm.2013.19.1.90

61. Kaneto H, Takahashi M, Watanabe J. The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. J Pharmacobiodyn. 1990;13(7):448–453. https://doi.org/10.1248/bpb1978.13.448